Content about Arthritis

April 8, 2014

Diplomat on Monday announced that it is one of a select group of specialty pharmacies contracted by Celgene to distribute Otezla (apremilast), a new medication for the treatment of psoriatic arthritis.

FLINT, Mich. — Diplomat on Monday announced that it is one of a select group of specialty pharmacies contracted by Celgene to distribute Otezla (apremilast), a new medication for the treatment of psoriatic arthritis. Otezla is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). 

Otezla was approved by the FDA on March 21, 2014, and is available in 10 mg, 20 mg and 30 mg tablets. 

April 3, 2014

Axium Healthcare Pharmacy announced that it will begin to dispense Otezla, the new oral therapy for the treatment of adults with active psoriatic arthritis.

LAKE MARY, Fla. — Axium Healthcare Pharmacy announced that it will begin to dispense Otezla, the new oral therapy for the treatment of adults with active psoriatic arthritis. Axium is one of a limited number of specialty pharmacies selected by drug manufacturer Celgene to dispense Otezla, which was approved by the Food and Drug Administration on March 21.

March 31, 2014

Just days after the Food and Drug Administration approved Otezla, a new oral therapy to treat active psoriatic arthritis in adult patients, Avella Specialty Pharmacy on Friday announced that it is prepared to begin distributing the drug.

PHOENIX — Just days after the Food and Drug Administration approved Otezla, a new oral therapy to treat active psoriatic arthritis in adult patients, Avella Specialty Pharmacy on Friday announced that it is prepared to begin distributing the drug. 

At this time, Avella is one of a select number of pharmacies that are contracted by Celgene, the drug manufacturer, to dispense the product at launch.

March 31, 2014

Greenstone announced the introduction of Piroxicam capsules to its generic pharmaceutical product line. The drug is offered in dosage strengths of 10 mg and 20 mg, and is the generic equivalent to Feldene.

PEAPACK, N.J. — Greenstone announced the introduction of Piroxicam capsules to its generic pharmaceutical product line. The drug is offered in dosage strengths of 10 mg and 20 mg, and is the generic equivalent to Feldene.

Piroxicam is intended for the relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis. This new, authorized generic adds to Greenstone’s growing line of products, and is backed by the distribution and customer service support of Pfizer Inc., the company said.

 

March 24, 2014

Celgene on Friday announced that the Food and Drug Administration has approved Otezla (apremilast), the company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of adult patients with active psoriatic arthritis.

SUMMIT, N.J. — Celgene on Friday announced that the Food and Drug Administration has approved Otezla (apremilast), the company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of adult patients with active psoriatic arthritis. A chronic disorder, psoriatic arthritis is characterized by pain, stiffness, swelling and tenderness of the joints, inflammation of specific ligaments and tendons, and a decrease in physical functioning. Otezla is the only FDA-approved oral treatment for psoriatic arthritis.

February 4, 2014

The Pharmaceutical Research and Manufacturers of America on Tuesday announced a partnership with the National Institutes of Health that will help spur drug development, the association stated.

WASHINGTON — The Pharmaceutical Research and Manufacturers of America on Tuesday announced a partnership with the National Institutes of Health that will help spur drug development, the association stated. 

The Accelerating Medicines Partnership — an initiative of NIH, several non-profit disease foundations, 10 biopharmaceutical companies and PhRMA — aims to transform the current model for developing new diagnostics and treatments by joining forces to identify and validate promising biological targets of disease. 

January 17, 2014

Nuvo Research on Friday announced that the U.S. Food and Drug Administration approved Mallinckrodt's new drug application for Pennsaid (diclofenac sodium topical solution) 2%

MISSISSAUGA, Ontario — Nuvo Research on Friday announced that the U.S. Food and Drug Administration approved Mallinckrodt's new drug application for Pennsaid (diclofenac sodium topical solution) 2%.

January 15, 2014

A new drug for autoimmune diseases from Antares Pharma that the company calls the first of its kind is now available, the drug maker said Wednesday.

EWING, N.J. — A new drug for autoimmune diseases from Antares Pharma that the company calls the first of its kind is now available, the drug maker said Wednesday.

Antares announced the availability of Otrexup for rheumatoid arthritis and psoriasis in adults and polyarticular idiopathic arthritis in children. The company said the drug is the first Food and Drug Administration-approved subcutaneous methotrexate product for once-weekly self-administration. Otrexup, which the FDA approved in October, is available with a single-dose auto injector.

December 4, 2013

Dennis Kinch lives by the motto, "Do what you can, when you can." These seven words have carried him through hardships and triumphs. In 2005-2006, they even spearheaded his crusade to walk the entire Route 66 to raise awareness about chronic pain.

Dennis Kinch lives by the motto, "Do what you can, when you can." These seven words have carried him through hardships and triumphs. In 2005-2006, they even spearheaded his crusade to walk the entire Route 66 to raise awareness about chronic pain.

November 26, 2013

Cardinal Health on Tuesday announced that it has renewed a three-year agreement with Prime Therapeutics to continue serving as the primary pharmaceutical supplier for Prime's pharmacy home-delivery service, PrimeMail, and for Prime Therapeutics Specialty Pharmacy.

DUBLIN, Ohio — Cardinal Health on Tuesday announced that it has renewed a three-year agreement with Prime Therapeutics to continue serving as the primary pharmaceutical supplier for Prime's pharmacy home-delivery service, PrimeMail, and for Prime Therapeutics Specialty Pharmacy.

November 5, 2013

Smooth Gator recently launched its Smooth Gator's 60 Second Pain Relief, a cream made with all-natural oils including wintergreen, aloe vera and eucalyptus.

ODESSA, Fla. — Smooth Gator recently launched its Smooth Gator's 60 Second Pain Relief, a cream made with all-natural oils including wintergreen, aloe vera and eucalyptus.  

November 5, 2013

A recently released clinical trial has found that patients taking a biotech drug for arthritis and those taking a biosimilar version had similar responses to both treatments.

LAKE FOREST, Ill. — A recently released clinical trial has found that patients taking a biotech drug for arthritis and those taking a biosimilar version had similar responses to both treatments.

October 29, 2013

Generic drug maker Amneal Pharmaceuticals is seeking Food and Drug Administration approval for a gout drug, prompting a lawsuit from the maker of the branded version, according to published reports.

NEW YORK — Generic drug maker Amneal Pharmaceuticals is seeking Food and Drug Administration approval for a gout drug, prompting a lawsuit from the maker of the branded version, according to published reports.

Law360 reported that Takeda Pharmaceuticals USA had sued Amneal in the U.S. District Court for the District of Delaware over the drug Colcrys (colchicine), used to treat gout and familial Mediterranean fever.

October 24, 2013

The Food and Drug Administration has approved a new formulation of a drug made by Genentech for rheumatoid arthritis that can be injected into the skin.

SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has approved a new formulation of a drug made by Genentech for rheumatoid arthritis that can be injected into the skin.

Genentech announced the approval of a subcutaneous formulation of Actemra (tocilizumab) in adults for adults with moderate RA who have not found sufficient relief by taking such disease-modifying antirheumatic drugs as methotrexate. Like the intravenous formulation of Actemra, the new version can be used alone or with drugs like methotrexate.

October 18, 2013

The Food and Drug Administration has approved a drug made by UCB for treating a form of arthritis.

ATLANTA — The Food and Drug Administration has approved a drug made by UCB for treating a form of arthritis.

The drug maker said Friday that the FDA had approved Cimzia (certolizumab pegol) for adults with active ankylosing spondylitis, though it declined to approve the drug for axial spondyloarthritis, or axSpA. UCB said it was working with the agency to determine how to get the drug approved for axSpA.

October 14, 2013

The Food and Drug Administration has approved a new drug made by Antares Pharma for treating rheumatoid arthritis and psoriasis, the drug maker said Monday.

EWING, N.J. — The Food and Drug Administration has approved a new drug made by Antares Pharma for treating rheumatoid arthritis and psoriasis, the drug maker said Monday.

October 8, 2013

GreenLight Rx is offering a line of medicine bottles aimed at elderly people and those suffering from such conditions as arthritis, the company said.

SANTA ANA, Calif. — GreenLight Rx is offering a line of medicine bottles aimed at elderly people and those suffering from such conditions as arthritis, the company said.

October 7, 2013

The National Psoriasis Foundation and the Arthritis Foundation are presenting the country's first program specifically devoted to psoriatic arthritis this week, the two organizations said Monday.

PORTLAND, Ore. — The National Psoriasis Foundation and the Arthritis Foundation are presenting the country's first program specifically devoted to psoriatic arthritis this week, the two organizations said Monday.

The groups will sponsor the event, Be Joint Smart, at Queens College in New York, on Saturday.

September 30, 2013

The Food and Drug Administration has approved a new usage for a drug made by UCB, the drug maker said Monday.

BRUSSELS — The Food and Drug Administration has approved a new usage for a drug made by UCB, the drug maker said Monday.

UCB announced the approval of Cimzia (certolizumab pegol) for psoriatic arthritis in adults. Psoriatic arthritis is an inflammatory, autoimmune condition that causes pain, swelling and stiffness around the joints, usually combined with the skin lesions of psoriasis. The drug was already approved to treat rheumatoid arthritis and Crohn's disease.

September 24, 2013

Belgian drug maker Ablynx is licensing an experimental treatment for rheumatoid arthritis and lupus to U.S. drug maker AbbVie in a deal worth up to $840 million.

GHENT, Belgium — Belgian drug maker Ablynx is licensing an experimental treatment for rheumatoid arthritis and lupus to U.S. drug maker AbbVie in a deal worth up to $840 million, the companies said.

The two drug makers announced that AbbVie would license the drug ALX-0061 for an upfront payment of $175 million plus milestone payments worth up to $665 million, as well as royalties. The drug belongs to a class known as anti-interleukin-6R nanobodies, which work by targeting an immune-system protein pathway that plays a key role in the inflammation associated with RA.

September 23, 2013

The Food and Drug Administration has approved a drug made by Johnson & Johnson for psoriatic arthritis, the company said Monday.

HORSHAM, Pa. — The Food and Drug Administration has approved a drug made by Johnson & Johnson for psoriatic arthritis, the company said Monday.

Janssen Biotech, a subsidiary of J&J, announced the approval of Stelara (ustekinumab) alone or combined with the common generic drug methotrexate for treating active psoriatic arthritis in adults. According to the National Psoriasis Foundation, the autoimmune disease is estimated to affect more than 2 million people in the United States and is characterized by joint inflammation and psoriasis skin lesions.

September 18, 2013

Two organizations are providing an educational program centered on a serious form of arthritis that affects up to 2 million people in the United States.

PORTLAND, Ore. — Two organizations are providing an educational program centered on a serious form of arthritis that affects up to 2 million people in the United States.

The National Psoriasis Foundation and the Arthritis Foundation said they would partner for the second year to educate residents of southern California about psoriatic arthritis, a chronic, inflammatory autoimmune disease that affects about 300,000 people in the state and 98,000 people in the Los Angeles area.

September 18, 2013

The Arthritis Society is donating more than C$4.5 million for arthritis research in Canada, the group said Wednesday.

TORONTO — The Arthritis Society is donating more than C$4.5 million for arthritis research in Canada, the group said Wednesday.

The organization, which is Canada's largest nongovernment funder of basic and applied arthritis researcher, said the funding will be used for established researchers and young investigators who are new to research. The amount is equivalent to US$4.36 million.

September 9, 2013

Minister of Health Rona Ambrose joined with Domenic Pilla, Shoppers Drug Mart president and CEO, on Monday in the launch of the company's Arthritis Screening program — a way for Canadians to work with a pharmacist to help detect arthritis early and manage their condition.

TORONTO — Minister of Health Rona Ambrose joined with Domenic Pilla, Shoppers Drug Mart president and CEO, on Monday in the launch of the company's Arthritis Screening program — a way for Canadians to work with a pharmacist to help detect arthritis early and manage their condition.

September 6, 2013

Expanding pharmacists' role in Canada could reduce the burden of chronic illness on patients and save the country's healthcare system between C$1.4 billion and C$1.9 billion (US$1.34 billion-$1.83 billion) over the next three years, according to a new report released by Arthritis Consumer Experts, the Arthritis Research Centre of Canada and Shoppers Drug Mart.

Canada's single-payer healthcare system is vastly different from that of the United States, not to mention differences between the two countries in terms of laws and regulations that govern pharmacy, but the lessons from the study apply equally to both.

Expanding pharmacists' role in Canada could reduce the burden of chronic illness on patients and save the country's healthcare system between C$1.4 billion and C$1.9 billion (US$1.34 billion to $1.83 billion) over the next three years, according to a new report released by Arthritis Consumer Experts, the Arthritis Research Centre of Canada and Shoppers Drug Mart.